View Post

Acquired ESR1 Mutations Predict Poor Benefit from Further AI Therapy in Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Christina Bennett, MS From: Patients with hormone receptor (HR) positive metastatic breast cancer who acquired ESR1 mutations during prior aromatase inhibitor therapy had worse survival when treated with the aromatase inhibitor exemestane compared with fulvestrant, a combined analysis of the phase 3 SoFEA and EFECT trials found. The results were recently reported in Clinical Cancer Research. The EFECT …